Nestlé files casein infant formula patent for better insulin sensitivity

By Annie Harrison-Dunn

- Last updated on GMT

Baby rats fed casein protein show better insulin sensitivity later in life than those fed whey, according to the research arm of infant formula giant Nestlé
Baby rats fed casein protein show better insulin sensitivity later in life than those fed whey, according to the research arm of infant formula giant Nestlé

Related tags Insulin sensitivity Milk Metabolic syndrome functional beverage beverage

Nestlé has filed an international patent for an infant nutrition product with casein protein, which it said could be used to prevent metabolic syndrome disorders later in life.

The patent, filed by Nestlé’s research arm Nestec, described the casein protein product as a “nutritional intervention”.

It said previous research has suggested bovine casein proteins could improve insulin sensitivity following energy restriction when compared to whey protein. What was not known however was the possible long-term consequences of early protein intake on insulin sensitivity under normal growth conditions.

“The present inventors have surprisingly shown that the feeding of casein early in life can improve glucose tolerance in short-term and improve insulin sensitivity in long-term, later in life. This is especially apparent when subjects are challenged with adipogenic diet in adult age, later in life,”​ the wrote.

Caseins are proteins commonly found in mammalian milk, including cow, goat, buffalo, sheep and human milk. The company proposed to use casein from cow’s milk, which was readily available commercially.

The patent referenced research on young rats fed a diet with casein protein, which suggested a protective effect on insulin sensitivity when they were exposed to an fat-inducing 'adipogenic' diet as adult rats. This was in contrast with rats fed whey protein, which displayed impaired insulin sensitivity as adults.

A window of opportunity

The company described the importance of ‘early programming’ in metabolic syndrome disorders and disease prevention, with prenatal and early postnatal periods being key windows of opportunity.

“It is now well recognised that suboptimal nutrition during critical periods of development may induce long-term alterations in organ structures or functions, which can predispose humans to later chronic diseases,”​ it wrote.

The patent also referenced the idea that certain infants may be more predisposed to these conditions due to genetic heritage. Earlier this year Nestlé announced it would contribute 22m Swiss francs (€18.31m) to a six-year multinational epigenetics research partnership​ with the hope of finding out more on how environmental factors like eating behaviours impacted genetics of the consumer and their future family.

Milking it?

According to UK National Health Service (NHS) advice, infant formula based mostly on casein is thought to take babies longer to digest than whey-based formula.

“It's not recommended for young babies, and there is little nutritional difference between this formula and first infant formula [for newborns]. Although it's often described as suitable for ‘hungrier babies’, there is no evidence that babies settle better or sleep longer when fed this type of formula.”


Source: WIPOPublication No. WO/2015/078974

Published: 4 June, 2015 Filed: 27 November, 2014
Infant nutrition improvement in insulin sensitivity later in life”
Authors: Nestec S.A. – F. Blancher, C. Mace and Y. Shahkhalili Dulloo 

Related news

Show more

Related products

show more

Nextida: Precision where it matters

Nextida: Precision where it matters

Content provided by Rousselot | 01-Jun-2024 | Product Brochure

NEXTIDA™ is an innovative platform of specific collagen peptide compositions with new targeted health benefits. Built and backed by science, Nextida stands...

Related suppliers

Follow us


View more